Compare Cassava Sciences Inc (FLNA) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs RLX Technology Inc — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while RLX Technology Inc trades at $2.02 (market cap $2.42B). The key difference: RLX Technology Inc is far larger — about 50.7× Cassava Sciences Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | RLX | |
|---|---|---|
Market Cap | $47.75M | $2.42B |
Sector | Health | Technology |
52-Week High | $4.64 | $2.73 |
52-Week Low | $0.87 | $1.79 |
Enterprise Value | -$34.93M | $1.04B |
Dividend Yield | — | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
RLX Technology trades at $2.02, up 1.0% with bearish technical signals despite recent earnings misses. The company maintains strong profitability with 22.47% net margins and international expansion driving revenue growth from $3.62B to $4.4B. Cash flow trends show operational strength but negative net cash flow. Analyst coverage remains limited with a single hold rating.
RLX faces execution risks from international integration while trading at reasonable valuations (P/E 17.96). The upcoming Q2 2026 earnings on August 14 will be crucial for validating growth trajectory amid competitive and regulatory pressures in the global e-vapor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
